Open access
Oct 2026
The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are foundational in treating patients with heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). One proposed mechanism behind the clinical effect is attenuation of fibrotic pathways. However, clinical data to support this mechanism are lac...
J. Jensen, C. Andersen, M. Omar et al.
· European Heart Journal · 0 citations